Recommended

Resilient supply: safeguarding Europe’s generics
Sanofi’s ‘factory of the future’ vision
AI Act: data governance and compliance implications
mRNA vaccine research cut by RFK Jr
EU Biotech Act public consultation opens
FDA PreCheck programme encourages new manufacturing sites
President Trump targets US pharma supply chain resilience
CDMO Ofichem acquires Uppsala site from Meribel
webinar

The analytical reality of recombinant endotoxin technologies

Supported by:

15 October 2020

Watch now
5
SHARES

Supported by:

15 October 2020

Watch now

ABOUT THIS WEBINAR

With the USP recently rejecting recombinant Factor C (rFC) as a compendial endotoxin test, the technology has been receiving more attention in the media and our industry. In late 2019, we presented our initial LAL and recombinant study data from global pharmaceutical organisations’ water samples. After a careful analysis of the data, we conducted a second, larger study with hundreds of global water samples evaluating the ruggedness, repeatability and specificity of commercially available rFC products, as well as our own recombinant product in development, against a large panel of endotoxins.  

In this webinar we discuss these results and learn where recombinant products stacked up against LAL when it comes to specificity and non-inferiority when testing relevant, real-world contaminated pharmaceutical water samples.

Learning outcomes of this webinar:

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

Endotoxin tests using recombinant technology have been receiving a lot of attention lately. After a careful analysis of our 2019 study on the alternative methods, we conducted a second, larger study with hundreds of global water samples evaluating rFC products, including our own in development. Sign up for our webinar to learn how they fared against the compendial method. 

Recombinant technology is a hot topic right now, but does that mean it is the best method of endotoxin testing? Join us for a discussion on how recombinant products stacked up against LAL when it comes to specificity and non-inferiority when tested in relevant, real-world contaminated pharmaceutical water samples.

Register

Register to watch this on-demand webinar

    Unless making a secure payment with your credit or debit card via a third-party payment processor, this form is not designed to collect confidential or sensitive personal information (e.g., financial information, social security numbers).

    *Required field

    Your details


    *


    *


    *


    *


    *



    *

    Other information

    Email preferences

    If you're not already opted-in to receive our emails, please select which types of communication you would like to receive:


    Confirm that you're human

    By clicking register, you consent to European Pharmaceutical Review contacting you about this and future webinars, and that you agree to our terms and conditions and privacy policy. Your information will be processed in accordance with GDPR and you can unsubscribe at any time.

    Speakers

    Nicola Reid Nicola Reid, Associate Director of Endotoxin products, Charles River

    Nicola Reid has over 20 years of experience with bacterial endotoxin testing and pharmaceutical microbiology. She has been involved in all aspects of the endotoxin assay, including the design and development of BET-specific instrumentation and software. Her work has led her to directing workshops and training courses, as well as lecturing internationally on a variety of BET-related topics including LAL methodologies, product validations, 21 CFR Part 11 and BET regulatory affairs.

    Share via
    Share via